Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of WST03 capsules plus metronidazole for bacterial vaginosis
CTR20263333Phase 2Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Sep 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WST03, metronidazole in bacterial vaginosis (BV), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Sep 2026; status: active.
02
Drugs
WST03metronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on CTR20263333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263333.